雙重腸泌素受體促效劑市場規模、佔有率、成長、全球產業分析、區域趨勢及2026-2034年預測

雙重腸泌素受體促效劑市場成長要素

全球雙重腸泌素受體促效劑市場預計在2025年達到365.1億美元，2026年成長至472.3億美元，2034年達到858億美元，預測期內複合年成長率為7.75%。北美將在2025年引領市場，佔全球銷售額的59.57%。

雙重腸泌素受體促效劑是一種先進的療法，它同時作用於兩種代謝激素通路，從而改善患者的血糖控制並顯著減輕體重。這些療法擴大用於治療第2型糖尿病、肥胖症和其他心血管代謝疾病。代謝性疾病盛行率的上升、醫生對雙重作用療法信心的增強以及法規核准範圍的擴大，都顯著推動了市場成長。製藥公司也大力投資臨床試驗、拓展適應症、提高產能和病患援助計畫。

主要市場趨勢

影響市場格局的最重要趨勢之一是人們對雙效代謝療法日益青睞的影響。醫療專業人員擴大採用能夠提供全面代謝效果的療法，例如控制血糖、減輕體重和改善心血管功能。

2025年11月，禮來公司宣布與美國政府達成協議，旨在改善患者獲得減肥藥的途徑。這凸顯了人們對先進的雙重腸促胰島素療法的接受度和需求日益成長。

市場促進因素

肥胖和第2型糖尿病的負擔日益加重

隨著全球肥胖和糖尿病盛行率的不斷上升，人們對能夠同時治療多種代謝紊亂的療法需求日益成長。雙重腸泌素受體促效劑不僅能有效控制血糖，還能顯著減輕體重。

2025年10月，信達生物公佈了馬度肽III期臨床試驗的正面結果。這些結果顯示，與索瑪魯肽相比，馬度胜肽在血糖控制和體重減輕方面表現更佳，進一步支持了此類藥物的治療潛力。

市場限制因素

高昂的醫療費用和保險報銷方面的挑戰

儘管臨床療效顯著，但高昂的治療費用仍是一大障礙。有限的保險覆蓋範圍、預先核准要求以及高額的自付費用限制了部分醫療系統的患者就醫。

例如，由於資金和服務能力的限制，英格蘭國家醫療服務體系 (NHS) 於 2025 年 3 月開始分階段推廣替澤帕肽，最初將處方限制在高優先級病患小組中。

市場機遇

肥胖症和 MASH/NASH 治療進展

隨著雙重腸泌素受體促效劑範圍從糖尿病管理擴展到肥胖症和代謝紊亂相關脂肪性肝炎（MASH/NASH）的治療，存在著巨大的機會。

2024年2月，勃林格殷格翰宣布了蘇沃度胜肽治療MASH的II期臨床試驗的令人鼓舞的結果。在該試驗中，高達83%的患者觀察到臨床症狀改善。

市場挑戰

生產能力和全球准入

對雙重腸促胰素療法的需求成長速度超過了生產能力的擴張速度。企業需要在擴大產能的同時，改善健保報銷機制和市場進入。

2024 年 6 月，禮來公司投資 90 億美元擴建位於印第安納州的生產設施，以提高替澤帕肽和未來代謝療法的產量。

細分分析

藥物

到 2025 年，由於其強大的市場佔有率、廣泛的臨床療效證明以及在治療肥胖症和糖尿病方面的適應症擴大，替澤帕肽佔了市場主導地位。

預計其他細分市場將實現最快成長，在預測期內複合年成長率將達到 21.43%。

疾病特異性

由於早期普及和醫生的廣泛支持，2 型糖尿病將在 2025 年佔最大的市場佔有率。

MASH/NASH 細分市場預計將以 22.49% 的複合年成長率成長，使其成為成長最快的適應症之一。

按年齡層

由於成人患者群體龐大且法規核准範圍廣泛，成人市場成為推動市場成長的主要因素。

在持續的臨床開發支持下，兒童市場預計將以 22.00% 的複合年成長率成長。

按類型

預計到 2025 年，品牌產品將佔收入的大部分，因為領先的雙重腸促胰島素療法仍將受到專利保護，來自學名藥的競爭將仍然很小。

透過行政途徑

皮下注射領域推動了市場的發展，這主要得益於注射療法（如替拉肽）的商業性成功。

透過分銷管道

由於患者對線上訂購、宅配和製造商支援的存取平台的需求不斷成長，線上藥局已經佔了市場主導地位。

區域分析

北美洲

北美仍然是最大的區域市場，預計到 2025 年將達到 217.5 億美元。高肥胖率、強大的醫療保健基礎設施以及創新代謝療法的快速普及繼續推動成長。

預計到 2026 年，美國市場規模將達到 247.4 億美元，約佔全球整體銷售額的 52.38%。

歐洲

預計到 2026 年，歐洲市場規模將達到 93 億美元，這得益於監管部門批准的增加和醫生採用率的提高。

• 英國：12.7億美元（2026年）
• 德國：16.6億美元（2026年）

亞太地區

預計到 2026 年，亞太地區的糖尿病市場規模將達到 73.7 億美元，主要得益於糖尿病患者人數的增加和產品供應範圍的擴大。

• 中國：20.6億美元（2026年）
• 日本：16.4億美元（2026年）
• 印度：8.1億美元（2026年）

拉丁美洲、中東和非洲

由於人們對肥胖症管理的認知不斷提高，以及醫療保健服務覆蓋範圍擴大，預計這些地區將實現穩步成長。

• 拉丁美洲：17.6億美元（2026年）
• 海灣合作理事會：5.4億美元（2026年）
• 南非：2.7億美元（2026年）

近期產業趨勢

• 2025 年 9 月：輝瑞收購了 Metser，以加強產品系列。
• 2025 年 8 月：Viking Therapeutics 報告了口服藥物 VK2735 的 II 期試驗的正面結果。
• 2025 年 7 月：恆瑞醫藥宣布其減肥藥HRS9531 的 III 期試驗取得正面結果。
• 2025 年 6 月：Altimmune 公司報告稱，pemvidutide 治療 MASH 的 IIb 期試驗取得了積極結果。
• 2025 年 3 月：羅氏與 Zealand Pharma 合作，共同開發 petrelintide 和 CT-388 的聯合治療。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場趨勢

第4章：主要考慮因素

• 主要疾病適應症的盛行率（按主要地區/國家分類）
• 新產品發布：按主要公司分類
• 主要地區和國家的監管情況概述
• 產業重大發展動態（合併、收購、合作、新產品發布等）
• 大型公司管道分析

第5章：全球雙重腸促促效劑市場分析、洞察與預測（2021-2034年）

• 市場分析、洞察與預測：按藥物分類
  • tirzepatide
  • Survodutide
  • 其他
• 市場分析、洞察與預測：按疾病分類。
  • 2型糖尿病
  • 肥胖
  • MASH/NASH
  • 其他
• 市場分析、洞察與預測：按年齡層別分類
  • 兒童
  • 成人
• 市場分析、洞察與預測：按類型
  • 品牌
  • 學名藥
• 市場分析、洞察與預測：按給藥途徑
  • 皮下
  • 口服
  • 其他
• 市場分析、洞察與預測：按分銷管道分類
  • 醫院藥房
  • 藥局和零售藥房
  • 專科藥房
  • 網路藥房
• 分析、洞察與預測：按地區分類
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第6章：北美雙重腸促促效劑市場分析、洞察與預測（2021-2034年）

• 國家
  • 美國
  • 加拿大

第7章：歐洲雙重腸促促效劑市場分析、洞察與預測（2021-2034年）

• 國家
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 斯堪地那維亞
  • 其他歐洲國家

第8章：亞太地區雙重腸促促效劑市場分析、洞察與預測（2021-2034年）

• 國家
  • 中國
  • 日本
  • 印度
  • 東南亞
  • 澳洲
  • 其他亞太國家

第9章：拉丁美洲雙重腸泌素受體促效劑市場分析、洞察與預測（2021-2034年）

• 國家
  • 巴西
  • 墨西哥
  • 其他拉丁美洲國家

第10章：中東和非洲雙重腸泌素受體促效劑市場分析、洞察與預測（2021-2034年）

• 國家
  • GCC
  • 南非
  • 其他中東和非洲國家

第11章 競爭分析

• 全球市佔率分析（2025 年）
• 公司簡介
  • Eli Lilly and Company
  • Innovent Biologics, Inc.
  • Boehringer Ingelheim International GmbH
  • Zealand Pharma A/S
  • Hanmi Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Altimmune, Inc.
  • Viking Therapeutics, Inc.
  • OPKO Health, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Growth Factors of dual incretin agonists Market

The global dual incretin agonists market was valued at USD 36.51 billion in 2025 and is projected to grow from USD 47.23 billion in 2026 to USD 85.80 billion by 2034, registering a CAGR of 7.75% during the forecast period. North America dominated the market in 2025, accounting for 59.57% of the global revenue share.

Dual incretin agonists are advanced therapies that target two metabolic hormone pathways simultaneously, helping patients achieve better blood glucose control and significant weight reduction. These therapies are increasingly used in the treatment of type 2 diabetes, obesity, and other cardiometabolic disorders. Rising prevalence of metabolic diseases, growing physician confidence in dual-action treatments, and expanding regulatory approvals are contributing significantly to market growth. Pharmaceutical companies are also investing heavily in clinical trials, label expansions, manufacturing capacity, and patient access programs.

Key Market Trends

One of the most significant trends shaping the market is the growing preference for dual-action metabolic therapies. Healthcare providers are increasingly adopting treatments capable of delivering comprehensive metabolic benefits, including glycemic control, weight loss, and cardiovascular improvements.

In November 2025, Eli Lilly and Company announced an agreement with the U.S. government to improve patient access to obesity medicines, highlighting the growing acceptance and demand for advanced dual incretin therapies.

Market Drivers

Rising Burden of Obesity and Type 2 Diabetes

The increasing global prevalence of obesity and diabetes is creating strong demand for therapies that address multiple metabolic conditions simultaneously. Dual incretin agonists provide effective blood sugar management while supporting significant weight reduction.

In October 2025, Innovent Biologics reported positive Phase III results for mazdutide, demonstrating superior glycemic control and weight loss compared to semaglutide, further validating the therapeutic potential of this drug class.

Market Restraints

High Treatment Costs and Reimbursement Challenges

Despite strong clinical benefits, the high cost of therapy remains a major barrier. Limited reimbursement coverage, prior authorization requirements, and high out-of-pocket expenses restrict patient access in several healthcare systems.

For example, NHS England introduced phased access to tirzepatide in March 2025, limiting initial prescribing to prioritized patient groups due to funding and service capacity constraints.

Market Opportunities

Expansion into Obesity and MASH/NASH Treatment

Significant opportunities exist as dual incretin agonists move beyond diabetes management into obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH).

In February 2024, Boehringer Ingelheim announced encouraging Phase II results for survodutide in MASH treatment, where up to 83% of patients showed clinical improvement.

Market Challenges

Manufacturing Capacity and Global Access

Demand for dual incretin therapies is rising faster than manufacturing capabilities. Companies must increase production capacity while simultaneously improving reimbursement and market access.

In June 2024, Eli Lilly and Company expanded its Indiana manufacturing facility with a USD 9 billion investment to boost production of tirzepatide and future metabolic therapies.

Segmentation Analysis

By Drug

Tirzepatide dominated the market in 2025 due to its strong commercial presence, broad clinical validation, and expanding indications across obesity and diabetes treatment.

The others segment is expected to register the fastest growth with a CAGR of 21.43% through the forecast period.

By Disease Indication

Type 2 diabetes accounted for the largest market share in 2025 due to early adoption and extensive physician acceptance.

The MASH/NASH segment is projected to expand at a CAGR of 22.49%, making it one of the fastest-growing applications.

By Age Group

The adult segment dominated the market due to a larger patient population and broader regulatory approvals.

The pediatric segment is expected to grow at a CAGR of 22.00%, supported by ongoing clinical development.

By Type

Branded products accounted for the majority of revenue in 2025 because leading dual incretin therapies remain protected by patents and face minimal generic competition.

By Route of Administration

The subcutaneous segment led the market owing to the commercial success of injectable therapies such as tirzepatide.

By Distribution Channel

Online pharmacies dominated due to increasing patient preference for digital ordering, home delivery, and manufacturer-supported access platforms.

Regional Analysis

North America

North America remained the largest regional market, reaching USD 21.75 billion in 2025. High obesity prevalence, strong healthcare infrastructure, and rapid adoption of innovative metabolic therapies continue to drive growth.

The U.S. market is estimated at USD 24.74 billion in 2026, representing approximately 52.38% of global revenue.

Europe

Europe is projected to reach USD 9.30 billion in 2026, supported by increasing regulatory approvals and physician adoption.

• United Kingdom: USD 1.27 billion (2026)
• Germany: USD 1.66 billion (2026)

Asia Pacific

Asia Pacific is forecast to reach USD 7.37 billion in 2026, driven by a growing diabetic population and expanding product availability.

• China: USD 2.06 billion (2026)
• Japan: USD 1.64 billion (2026)
• India: USD 0.81 billion (2026)

Latin America and Middle East & Africa

These regions are expected to witness steady growth due to increasing awareness of obesity management and expanding healthcare access.

• Latin America: USD 1.76 billion (2026)
• GCC: USD 0.54 billion (2026)
• South Africa: USD 0.27 billion (2026)

Competitive Landscape

The market is highly consolidated and led by major pharmaceutical companies investing heavily in clinical development, manufacturing expansion, and strategic partnerships.

Key companies operating in the market include:

• Eli Lilly and Company
• Innovent Biologics, Inc.
• Boehringer Ingelheim International GmbH
• Zealand Pharma A/S
• Hanmi Pharmaceutical Co., Ltd.
• Merck & Co., Inc.
• Altimmune, Inc.
• Viking Therapeutics, Inc.
• OPKO Health, Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Recent Industry Developments

• September 2025: Pfizer acquired Metsera to strengthen its obesity and cardiometabolic portfolio.
• August 2025: Viking Therapeutics reported positive Phase II results for oral VK2735.
• July 2025: Hengrui Medicine announced successful Phase III results for HRS9531 in obesity treatment.
• June 2025: Altimmune reported positive Phase IIb results for pemvidutide in MASH.
• March 2025: Roche partnered with Zealand Pharma to co-develop petrelintide and CT-388 combination therapies.

Conclusion

The dual incretin agonists market is entering a phase of rapid expansion as healthcare systems increasingly focus on integrated management of obesity, type 2 diabetes, and cardiometabolic disorders. Valued at USD 36.51 billion in 2025, the market is expected to reach USD 47.23 billion in 2026 and further expand to USD 85.80 billion by 2034. Strong clinical outcomes, growing physician adoption, expanding indications, and continued investments by leading pharmaceutical companies are expected to drive long-term growth. Although high treatment costs and manufacturing scalability remain challenges, ongoing innovation and broader patient access initiatives are likely to strengthen market penetration and create substantial opportunities throughout the forecast period.

Segmentation By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug * Tirzepatide

• Survodutide
• Others

By Disease Indication * Type 2 Diabetes

• Obesity
• MASH/NASH
• Others

By Age Group * Pediatric

• Adults

By Type * Branded

• Generic

By Route of Administration * Subcutaneous

• Oral
• Others

By Distribution Channel * Hospital Pharmacies

• Drug Stores & Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By Region * North America (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disease Indications, By Key Regions/ Countries
• 4.2. New Product Launches, By Key Players
• 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.5. Pipeline Analysis, By Key Players

5. Global Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Tirzepatide
  • 5.1.2. Survodutide
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Type 2 Diabetes
  • 5.2.2. Obesity
  • 5.2.3. MASH/NASH
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generics
• 5.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.5.1. Subcutaneous
  • 5.5.2. Oral
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Drug Stores & Retail Pharmacies
  • 5.6.3. Specialty Pharmacies
  • 5.6.4. Online Pharmacies
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Tirzepatide
  • 6.1.2. Survodutide
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Type 2 Diabetes
  • 6.2.2. Obesity
  • 6.2.3. MASH/NASH
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generics
• 6.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.5.1. Subcutaneous
  • 6.5.2. Oral
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Drug Stores & Retail Pharmacies
  • 6.6.3. Specialty Pharmacies
  • 6.6.4. Online Pharmacies
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. Tirzepatide
  • 7.1.2. Survodutide
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Type 2 Diabetes
  • 7.2.2. Obesity
  • 7.2.3. MASH/NASH
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generics
• 7.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.5.1. Subcutaneous
  • 7.5.2. Oral
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Drug Stores & Retail Pharmacies
  • 7.6.3. Specialty Pharmacies
  • 7.6.4. Online Pharmacies
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Tirzepatide
  • 8.1.2. Survodutide
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Type 2 Diabetes
  • 8.2.2. Obesity
  • 8.2.3. MASH/NASH
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generics
• 8.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.5.1. Subcutaneous
  • 8.5.2. Oral
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Drug Stores & Retail Pharmacies
  • 8.6.3. Specialty Pharmacies
  • 8.6.4. Online Pharmacies
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. Tirzepatide
  • 9.1.2. Survodutide
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Type 2 Diabetes
  • 9.2.2. Obesity
  • 9.2.3. MASH/NASH
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generics
• 9.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.5.1. Subcutaneous
  • 9.5.2. Oral
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Drug Stores & Retail Pharmacies
  • 9.6.3. Specialty Pharmacies
  • 9.6.4. Online Pharmacies
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug
  • 10.1.1. Tirzepatide
  • 10.1.2. Survodutide
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Type 2 Diabetes
  • 10.2.2. Obesity
  • 10.2.3. MASH/NASH
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generics
• 10.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.5.1. Subcutaneous
  • 10.5.2. Oral
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Drug Stores & Retail Pharmacies
  • 10.6.3. Specialty Pharmacies
  • 10.6.4. Online Pharmacies
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Eli Lilly and Company
  • 11.2.2. Innovent Biologics, Inc.
  • 11.2.3. Boehringer Ingelheim International GmbH
  • 11.2.4. Zealand Pharma A/S
  • 11.2.5. Hanmi Pharmaceutical Co., Ltd.
  • 11.2.6. Merck & Co., Inc.
  • 11.2.7. Altimmune, Inc.
  • 11.2.8. Viking Therapeutics, Inc.
  • 11.2.9. OPKO Health, Inc.
  • 11.2.10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

List of Tables

• Figure 1: Global Dual Incretin Agonists Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
• Figure 2: Global Dual Incretin Agonists Market Value Share (%), by Drug, 2025 & 2034
• Figure 3: Global Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025 & 2034
• Figure 4: Global Dual Incretin Agonists Market Value Share (%), by Age Group, 2025 & 2034
• Figure 5: Global Dual Incretin Agonists Market Value Share (%), by Type, 2025 & 2034
• Figure 6: Global Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025 & 2034
• Figure 7: Global Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025 & 2034
• Figure 8: Global Dual Incretin Agonists Market Value Share (%), by Region, 2025 & 2034
• Figure 9: North America Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
• Figure 10: North America Dual Incretin Agonists Market Value Share (%), by Drug, 2025
• Figure 11: North America Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
• Figure 12: North America Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
• Figure 13: North America Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
• Figure 14: North America Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
• Figure 15: North America Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
• Figure 16: North America Dual Incretin Agonists Market Value Share (%), by Type, 2025
• Figure 17: North America Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
• Figure 18: North America Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
• Figure 19: North America Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 20: North America Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
• Figure 21: North America Dual Incretin Agonists Market Value (USD billion), by Country, 2025 & 2034
• Figure 22: North America Dual Incretin Agonists Market Value Share (%), by Country, 2025
• Figure 23: Europe Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
• Figure 24: Europe Dual Incretin Agonists Market Value Share (%), by Drug, 2025
• Figure 25: Europe Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
• Figure 26: Europe Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
• Figure 27: Europe Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
• Figure 28: Europe Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
• Figure 29: Europe Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
• Figure 30: Europe Dual Incretin Agonists Market Value Share (%), by Type, 2025
• Figure 31: Europe Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
• Figure 32: Europe Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
• Figure 33: Europe Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 34: Europe Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
• Figure 35: Europe Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
• Figure 36: Europe Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
• Figure 37: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
• Figure 38: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Drug, 2025
• Figure 39: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
• Figure 40: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
• Figure 41: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
• Figure 42: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
• Figure 43: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
• Figure 44: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Type, 2025
• Figure 45: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
• Figure 46: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
• Figure 47: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 48: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
• Figure 49: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
• Figure 50: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
• Figure 51: Latin America Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
• Figure 52: Latin America Dual Incretin Agonists Market Value Share (%), by Drug, 2025
• Figure 53: Latin America Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
• Figure 54: Latin America Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
• Figure 55: Latin America Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
• Figure 56: Latin America Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
• Figure 57: Latin America Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
• Figure 58: Latin America Dual Incretin Agonists Market Value Share (%), by Type, 2025
• Figure 59: Latin America Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
• Figure 60: Latin America Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
• Figure 61: Latin America Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 62: Latin America Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
• Figure 63: Latin America Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
• Figure 64: Latin America Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
• Figure 65: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
• Figure 66: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Drug, 2025
• Figure 67: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
• Figure 68: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
• Figure 69: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
• Figure 70: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
• Figure 71: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
• Figure 72: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Type, 2025
• Figure 73: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
• Figure 74: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
• Figure 75: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 76: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
• Figure 77: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
• Figure 78: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
• Figure 79: Global Dual Incretin Agonists Market Share (%), by Company, 2025